Serum AFU, 5’-NT and AFP as biomarkers for primary hepatocellular carcinoma diagnosis

Abstract

<jats:title>Abstract</jats:title><jats:p>To evaluate the clinical value of serum α-L-fucosidase (AFU), 5’-nucleotidase (5’-NT) and alpha fetoprotein (AFP) as biomarkers for primary hepatocellular carcinoma (PHC) diagnosis. Methods: Thirty six primary hepatocellular carcinoma (PHC) patients and 36 healthy controls were recruited in this study from February 2014 to January 2016 in the Second People’s Hospital of Tianjin. The serum level of AFU, 5’-NT and AFP were examined and compared between the two groups. The diagnostic sensitivity, specificity area under the receiver operating characteristic (ROC) curve were calculated by STATA11.0 software. Results: The serum level of AFU, 5’-NT, AFP were 30.87±10.43(U/L), 5.58±3.89(U/L), 233.60±226.60 (μg/L) respectively for primary hepatocellular carcinoma group and 19.96±6.73 (U/L), 1.87±0.84 (U/L), 16.64±14.17 (μg/L) for healthy control groups. The serum level of AFU, 5’-NT and AFP in primary hepatocellular carcinoma group were significant higher than those of healthy control group (P&lt;0.001). The diagnostic sensitivity and specificity were 0.78 (95%CI:l0.61-0.90), 0.64 (95%CI:0.46-0.79) for serum AFU, 0.75(95%CI:0.58-0.88), 0.72(95%CI:0.55- 0.86) for serum 5’-NT and 0.72 (95%CI:0.55-0.86), 0.92 (95%CI:0.78-0.98) for serum AFP respectively. The AUC under the ROC curve were 0.80 (0.69-0.90), 0.80 (0.69-0.91) and 0.87 (0.780-0.96) for serum AFU, 5’-NT and AFP respectively. Positive correlation between AFU and 5’-NT (rpearson=0.63, P&lt;0.05), AFU and AFP (rpearson=0.49, P&lt;0.05), 5’-NT and AFP(rpearson=0.44, P&lt;0.05) were found in the primary hepatocellular carcinoma patients. Conclusion: Serum AFU, 5’-NT and AFP were higher in PHC patients than those of healthy controls. The difference between PHC patients and healthy controls made serum AFU, 5’-NT and AFP potential biomarker for PHC diagnosis.</jats:p>

Plasma α‐L‐fucosidase‐1 in patients with Sjögren's syndrome and other rheumatic disorders

“…With the help of different diametric, round‐ended ophthalmologic lacrimal sac probes first used by our group, parotid sialography with the use of 1.5‐2 mL Dionosyl‐F‐Aquosum, water‐solvent contrast substance, was carried out. In those patients with SS, we reinforced the diagnosis at the fulfillment of a least 4 criteria in accordance with current diagnostic consensus guidelines and following recommendations to avoid misdiagnosis with other disorders including RA, particularly in children …”

“…Pediatric subjects ranging from 2.5 to 10 years and were ≤18 years old, were included in the study only after signed informed consent of both their related parents or tutors was given. Fucosidase diagnosis was performed according to the previously reported methods . SS in children was diagnosed with the concurrent or alternative presence of bilateral parotid glands associated with dryness of mouth and/or eyes and with at least 1 of these tests (antinuclear antibodies, anti‐double‐stranded DNA, anti‐SSA, anti‐SSB) positive at ≥1:80 …”

“…In those patients with SS, we reinforced the diagnosis at the fulfillment of a least 4 criteria in accordance with current diagnostic consensus guidelines and following recommendations to avoid misdiagnosis with other disorders including RA, particularly in children. [20][21][22][23][24][25] The plasma enzyme activity of α-L-FUCA-1 was investigated in the Laboratory of the Pediatrics Department with a fluorimetric method. 26 The blood specimens were processed within 1-2 hours from the withdrawal and using sterile disposable plastic ware.…”

“…Fucosidase diagnosis was performed according to the previously reported methods. 1,20 SS in children was diagnosed with the concurrent or alternative presence of bilateral parotid glands associated with dryness of mouth and/or eyes and with at least 1 of these tests (antinuclear antibodies, anti-double-stranded DNA, anti-SSA, anti-SSB) positive at ≥1:80. 21…”

PLK1 Is Implicated in the Poor Prognosis of Hepatocellular Carcinoma

“…Therefore, it is significant to investigate the novel key genes and major signal pathways involving in the development of HCC. To date, serum alpha-fetoprotein (AFP) and PIVKA-II (protein induced by vitamin K absence or antagonist-II) are two best used biomarker for HCC in clinical screening [5]- [10]. The combination use of the both biomarkers has significantly improved HCC sensitivity detection despite that their sensitivity and specificity are far from satisfactory [11] [12] [13] [14].…”